Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2022 - 2023)

Historic Preferred Stock Liabilities for Gyre Therapeutics (GYRE) over the last 5 years, with Q4 2023 value amounting to $64.5 million.

  • Gyre Therapeutics' Preferred Stock Liabilities rose 9371.64% to $64.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $64.5 million, marking a year-over-year increase of 9371.64%. This contributed to the annual value of $64.5 million for FY2023, which is 9371.64% up from last year.
  • Gyre Therapeutics' Preferred Stock Liabilities amounted to $64.5 million in Q4 2023, which was up 9371.64% from $33.3 million recorded in Q2 2023.
  • Gyre Therapeutics' Preferred Stock Liabilities' 5-year high stood at $64.5 million during Q4 2023, with a 5-year trough of $33.3 million in Q4 2022.